Jamjoom Pharma offers a compelling investment opportunity, underpinned by strong financial performance, strategic growth initiatives, and a proven track record of delivering value to stakeholders. Our position as a leading pharmaceutical company in the Middle East and Africa region makes us uniquely suited to capitalize on emerging opportunities in the global healthcare sector.
Consistent revenue growth with SAR 1.3 billion in 2024, reflecting a robust 19.8% YoY increase.
High profitability with a net profit margin of 27% and an EBITDA margin of 33.2%.
Strong free cash flow conversion of 87%, demonstrating financial stability and operational efficiency.
Dominant market share in key therapeutic areas such as ophthalmology and dermatology.
Expanding footprint across 36 countries with significant growth in high-potential markets like Egypt, Algeria, and the Gulf.
Established partnerships with healthcare providers and government agencies to drive regional market leadership.
Launch of 9 new brands in 2024, including advancements in consumer health and anti-diabetics.
Robust pipeline targeting high- growth areas such as Cardiovascular, gastrointestinal, and biologics.
Commitment to addressing unmet medical needs through continuous R&D investments.
Fully operational Jeddah Sterile Facility, enabling production of high- demand ophthalmology products.
Expansion of manufacturing capacity in Egypt to support regional self- sufficiency and market demand.
Al-driven technologies enhancing operational efficiency and scalability.
Key contributor to Saudi Vision 2030 goals by promoting local pharmaceutical manufacturing and job creation.
Commitment to sustainable practices, including energy-efficient production and reduced environmental impact.
Led by an experienced management team with a proven track record of delivering results.
Strong corporate governance framework, ensuring transparency and accountability.
High-growth opportunities in underserved regions, supported by tailored market-entry strategies.
Strategic focus on expanding presence in Francophone Africa and other emerging markets.
